Journal of Gastrointestinal Cancer最新文献

{"title":"Anal Verrucous Carcinoma: A Case Report and a Systematic Review of the Literature.","authors":"Ioannis D Gkegkes, Nikolaos Katsoulas, Dimitrios Vlachodimitropoulos, Apostolos P Stamatiadis","doi":"10.1007/s12029-025-01272-2","DOIUrl":"https://doi.org/10.1007/s12029-025-01272-2","url":null,"abstract":"<p><strong>Background: </strong>Αn uncommon variant of squamous cell carcinoma is represented by verrucous carcinoma. Regarding the anal and perianal area, verrucous carcinoma is rarely described in the literature.</p><p><strong>Methods: </strong>A systematic PubMed and Scopus search was performed, a propos of a case report.</p><p><strong>Results: </strong>A 39-year-old man presented to our proctology practice, complaining of a palpable, perianal lump. A small size of the lesion was decided to be excised, under local anaesthesia. Pathology revealed the presence of verrucous carcinoma. Thirty patients from 17 studies were included. The mean age of the patients was 47.4 years (range: 33-77). The majority of them were males (24 out of 30, 80%). Considering the comorbidities of the included patients, only in 4 patients were mentioned to have a history of multiple perianal fistulas due to Crohn's disease, colorectal cancer, heart-lung transplantation and hidradenitis suppurativa, respectively. The most frequent symptoms at the time of presentation were painless perianal mass (7 out of 30, 23.3%), perianal pain (5 out of 30, 16.7%), ulcerated / exophytic mass (4 out of 30, 13.3%), pruritus ani (2 out of 30, 6.7%), perianal sepsis (1 out of 30, 10%) and bleeding (1 out of 30, 10%). The duration of the symptoms ranged between 2 months and 14 years. Regarding the surgical treatment of the included patients, local excision was the most common surgical option (76.7%). Combined chemoradiotherapy was administered in 5 out of 30 patients (16.7%). Recurrence of the disease was reported in 5 out of 30 patients (16.7%). Death was reported in 3 out of 30 cases (10%).</p><p><strong>Conclusion: </strong>Αnal verrucous carcinoma (VC) is an extremely rare neoplasm of the perianal area. In most of the cases, early diagnosis of VC is difficult due to the fact that its appearance and its symptoms commonly mimic benign conditions. Histopathological confirmation is the principal requisite in any further therapeutic treatment. In general, the prognosis is relatively good, especially when an early and radical excision is performed.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"152"},"PeriodicalIF":1.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Versus Laparoscopic Lateral Lymph Node Dissection for Advanced Pelvic Cancers: a Systematic Review and Meta-analysis.","authors":"Mohamed Ali Chaouch, Paul Leblanc-Even, Ahmed Loghmari, Adriano Carneiro da Costa, Alessandro Mazzotta, Salah Khayat, Bassem Krimi, Amine Gouader, Jim Khan, Christoph Reissfelder, Wahid Fattal, Hani Oweira","doi":"10.1007/s12029-025-01251-7","DOIUrl":"https://doi.org/10.1007/s12029-025-01251-7","url":null,"abstract":"<p><strong>Background: </strong>Lateral pelvic lymph node dissection (LPND) is a key component in the surgical treatment of advanced pelvic malignancies. Minimally invasive techniques have evolved over the past decade, with laparoscopic surgery as the traditional standard and robotic-assisted surgery emerging as a promising alternative. This study aimed to systematically compare robotic (R-LPND) and laparoscopic (L-LPND) approaches in terms of perioperative outcomes in patients undergoing LPND for advanced pelvic cancers.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. The search was performed until April 1, 2024. The primary outcome was postoperative morbidity. Secondary outcomes included operative time, LPND-specific operative time, hospital stay duration, number of lymph nodes harvested, and rate of major complications.</p><p><strong>Results: </strong>Eleven studies with 667 robotic and 568 laparoscopic cases were included. Robotic LPND was associated with significantly lower postoperative morbidity (OR 0.52; p = 0.02) and shorter hospital stays (MD - 2.30 days; p = 0.0003). However, robotic procedures had significantly longer operative times (MD 40.58 min; p = 0.003). No significant differences were observed in the number of lymph nodes harvested, LPND time, or rates of major complications. Heterogeneity was moderate to high for most outcomes, and the overall certainty of evidence ranged from low to moderate.</p><p><strong>Conclusion: </strong>Robotic LPND may offer clinical benefits in terms of reduced morbidity and shorter hospitalization compared to laparoscopic surgery, although it is associated with longer operative time. These findings are based on evidence of low to moderate certainty and should be interpreted with caution due to the predominance of retrospective studies and notable inter-study heterogeneity.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"151"},"PeriodicalIF":1.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Circulating Tumor DNA Mutations in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis Based on Time-To-Event Data.","authors":"Gustavo Tadeu Freitas Uchôa Matheus, Danilo Monteiro Ribeiro, Ana Luiza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Isabela Junger Meirelles Aguiar, Pedro Henrique de Souza Wagner, Rommel Mario Rodríguez Burbano, Francisco Cezar Aquino de Moraes","doi":"10.1007/s12029-025-01271-3","DOIUrl":"10.1007/s12029-025-01271-3","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the digestive tract, most commonly originating in the stomach or small intestine, and driven by activating mutations in the KIT or PDGFRA genes. Liquid biopsy has emerged as a promising, minimally invasive technique to detect and monitor circulating tumor DNA (ctDNA), offering real-time insights into tumor dynamics and treatment response. Specifically, detecting KIT/PDGFRA mutations in ctDNA may aid in assessing prognosis, therapeutic response, and resistance. However, the clinical utility of this approach remains unclear. To address this, we conducted a systematic review and meta-analysis to evaluate the prognostic relevance of ctDNA mutations in GIST patients by comparing survival outcomes between those with KIT/PDGFRA mutations and those with wild-type profiles or no detectable ctDNA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A comprehensive systematic search was performed in the PubMed, Scopus, and Web of Science databases to identify studies evaluating overall survival (OS) at different time points in patients with GIST, stratified by ctDNA status (ctDNA-negative vs. ctDNA-positive). Hazard ratios (HRs) were extracted or calculated, and Kaplan-Meier curves were reconstructed using an adjusted Cox proportional hazards model, with 95% confidence intervals (CIs). A p-value &lt; 0.05 was considered statistically significant. All statistical analyses were performed using RStudio software, version 4.2.3.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study included seven eligible studies comprising a total of 2024 histologically confirmed GIST patients, of whom 1610 were classified as ctDNA-positive and 414 had no detectable ctDNA mutations. OS at different time points was consistently more favorable in the ctDNA-negative group compared to the ctDNA-positive group (reference). The pooled hazard ratios (HR) were as follows: at 1year, HR 0.91 (95% CI: 0.89-0.93; p &lt; 0.01; I&lt;sup&gt;2&lt;/sup&gt; = 0%); at 2years, HR 0.85 (95% CI: 0.83-0.88; p &lt; 0.01; I&lt;sup&gt;2&lt;/sup&gt; = 20%); at 3years, HR 0.77 (95% CI: 0.74-0.81; p &lt; 0.01; I&lt;sup&gt;2&lt;/sup&gt; = 28.2%); and at 5years, HR 0.63 (95% CI: 0.54-0.73; p &lt; 0.01; I&lt;sup&gt;2&lt;/sup&gt; = 70.8%). At maximum follow-up (mean follow-up of 7.5months), OS showed a 49% reduction in survival in the ctDNA-positive group (HR 0.51; 95% CI: 0.40-0.64; p &lt; 0.01; I&lt;sup&gt;2&lt;/sup&gt; = 79.9%). Additionally, in a pooled analysis of Kaplan-Meier data from patients with the KIT exon 11 (KIT11) mutation, the adjusted Cox proportional hazards model estimated an HR of 0.66 (95% CI: 0.49-0.89; p = 0.007), favoring the ctDNA-positive group.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This meta-analysis highlights the potential of ctDNA as a prognostic biomarker in GIST, showing that its presence is consistently associated with poorer survival outcomes across mutational subtypes. These findings support the integration of ctDNA analysis into clinical practice as a minimally invasive tool for d","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"153"},"PeriodicalIF":1.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Submucosal Dissection Followed by Chemoradiotherapy Versus Radiotherapy in Patients with Stage T1bN0M0 Esophageal Cancer.","authors":"Yan Lin, Cheng-Xian Ma, Huan-Wei Liang, Wei Huang, Xin-Bin Pan","doi":"10.1007/s12029-025-01270-4","DOIUrl":"https://doi.org/10.1007/s12029-025-01270-4","url":null,"abstract":"<p><strong>Purpose: </strong>To compare survival outcomes between endoscopic submucosal dissection (ESD) followed by chemoradiotherapy versus radiotherapy in stage T1bN0M0 esophageal cancer.</p><p><strong>Materials and methods: </strong>Patients with stage T1bN0M0 esophageal cancer between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Cancer-specific survival (CSS) and overall survival (OS) were compared between the ESD followed by chemoradiotherapy versus radiotherapy cohorts.</p><p><strong>Results: </strong>Among 71 eligible patients, 57 (80.3%) received ESD followed by chemoradiotherapy and 14 (19.7%) underwent ESD followed by radiotherapy. Before propensity score matching, ESD followed by radiotherapy demonstrated inferior 5-year CSS (hazard ratio [HR] = 3.27, 95% confidence interval [CI] 1.12-9.58, P = 0.030), but comparable 5-year OS (HR = 1.46; 95% CI, 0.65-3.27; P = 0.362) versus ESD followed by chemoradiotherapy. After propensity score matching, no significant difference in 5-year CSS (HR = 1.76; 95% CI, 0.49-6.34; P = 0.386) or OS (HR = 1.33; 95% CI, 0.48-3.74; P = 0.585) was observed between treatment groups.</p><p><strong>Conclusion: </strong>ESD followed by radiotherapy provides equivalent CSS and OS compared to ESD followed by chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"150"},"PeriodicalIF":1.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome Analysis of Gastric Cancer in the Oldest-Old: The Role of Proactive Surveillance and Future Directions.","authors":"Masayuki Urabe, Yojiro Hashiguchi","doi":"10.1007/s12029-025-01276-y","DOIUrl":"https://doi.org/10.1007/s12029-025-01276-y","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"149"},"PeriodicalIF":1.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toripalimab in Esophageal Cancer: A Systematic Review and Meta-Analysis.","authors":"Mostafa A Khalifa, Marafi Jammaa Ahmed, Hashim Talib Hashim, Aya Ahmed Shimal, Ahmad Omar Saleh, Salma Allam, Elian Khalafalla Awadalla, Hadeel Basheer Bin Saud, Jubran Khaled Alzedaar, Ali Dway, Roaa Abdultawab, Asala Hussein Al-Hadrawi, Mohammedbaqer Ghuraibawi","doi":"10.1007/s12029-025-01263-3","DOIUrl":"10.1007/s12029-025-01263-3","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer (EC) remains a highly aggressive malignancy with a poor prognosis despite advancements in treatment. Toripalimab, a PD-1 inhibitor, has demonstrated the potential to improve clinical outcomes. This systematic review and meta-analysis assess the efficacy and safety of Toripalimab in EC.</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, we conducted a systematic review and meta-analysis, searching PubMed, Embase, Scopus, ScienceDirect, and Google Scholar up to January 2025. Eligible studies evaluated Toripalimab in esophageal cancer, including randomized controlled trials and non-randomized controlled trials. Primary outcomes included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), while safety outcomes assessed treatment-related adverse events. Data were synthesized using random-effects models, with heterogeneity evaluated via Cochrane's Q and I² statistics.</p><p><strong>Results: </strong>The pooled analysis included six studies involving 678 patients. Toripalimab demonstrated promising efficacy, with a Complete Response (CR) rate of 33%, Partial Response (PR) rate of 36%, pathological complete response (pCR) rate of 30%, and major pathological response (MPR) rate of 46%. The R0 resection rate was 87%, while OS and PFS rates were reported at 78% and 50%, respectively. Anemia (56%), alopecia (54%), leukopenia (54%), and fatigue (30%) were the most frequently reported adverse effects. Other common adverse effects included nausea (29%), constipation (18%), and vomiting (20%).</p><p><strong>Conclusions: </strong>Toripalimab demonstrates significant potential in treating esophageal cancer, with favorable response rates and survival outcomes. However, the high incidence of adverse effects highlights the need for supportive care and ongoing research. While based on limited sample sizes and single-arm studies that may introduce bias and affect generalizability in this review, we provide valuable preliminary insights into toripalimab's potential, highlighting the need for larger randomized trials to build on these findings.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"148"},"PeriodicalIF":1.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes During Neoadjuvant Therapy for Gastrointestinal Cancer and Their Association with Postoperative Complications.","authors":"Alexander H Shannon, Samantha M Ruff, Marilly Palettas, Angela Sarna, Emily Huang, Peter J Kneuertz, Mary Dillhoff, Aslam Ejaz, Timothy M Pawlik, Jordan M Cloyd","doi":"10.1007/s12029-025-01268-y","DOIUrl":"10.1007/s12029-025-01268-y","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant therapy (NT) given before surgery for gastrointestinal (GI) malignancies can lead to adverse events. Whether patient-reported outcomes (PRO) or quality of life (QOL) during NT is predictive of postoperative complications is unknown.</p><p><strong>Methods: </strong>A planned secondary analysis of patients with GI cancers undergoing NT utilized a customized mobile-phone application (app) to measure real-time PROs and monthly QOL using FACT-G (Functional Assessment of Cancer Therapy-General). Among surgical patients, the association between QOL and PROs and postoperative Clavien-Dindo grade ≥ 2 complications was analyzed using univariate analyses.</p><p><strong>Results: </strong>Among 104 patients enrolled, 69 (66%) underwent surgery following NT and 20 (28.9%) experienced 30-day complications. There were no differences in baseline demographics, NT duration, or cancer type between Complications and No Complications groups (all p > 0.05). QOL scores at NT start (mean FACT-G Complications 76.1 vs No Complications 75.2), and changes in QOL during NT did not differ between the two cohorts (p > 0.05). PRO entries of those who experienced complications were more likely to report lack of appetite (25.9% vs 14.2%; p < 0.001) and pain (36.6% vs 18.7%; p < 0.001) but less likely to report fatigue (31.9% vs 41.6%; p = 0.009), anxiety (18.1% vs 39.1%; p < 0.001), trouble sleeping (20.8% vs 39.1%; p < 0.001), lack of focus (5.6% vs 18.5%; p < 0.001), depression (0.5% vs 14%; p < 0.001), and frustration (13.9% vs 21.4%; p = 0.01).</p><p><strong>Conclusion: </strong>In this prospective cohort study, specific PROs were associated with postoperative complications among those who underwent surgical resection. Further research is needed to assess whether preoperative PROs can guide patient-centered interventions mitigating postoperative complications.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"146"},"PeriodicalIF":1.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Neoadjuvant Therapy for Patients with Adenosquamous Carcinoma of the Pancreas: Outcomes from the National Cancer Database.","authors":"Amanda K Walsh, Diamantis I Tsilimigras, Alex B Blair, Susan Tsai, Timothy M Pawlik, Ashish Manne, Shafia Rahman, Eric D Miller, Kenneth L Pitter, Jordan M Cloyd","doi":"10.1007/s12029-025-01269-x","DOIUrl":"10.1007/s12029-025-01269-x","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic adenosquamous carcinoma (PASC) is a rare and aggressive form of pancreatic cancer whose management often follows its more common pancreatic ductal adenocarcinoma (PDAC) counterpart. While neoadjuvant therapy (NT) is increasingly utilized prior to surgery for PDAC, whether patients with PASC experience similar benefits is unclear.</p><p><strong>Methods: </strong>Using the National Cancer Database (NCDB), all patients with stage I-III PASC who underwent surgical resection between 2006 and 2020 were included. Patient and tumor characteristics and overall survival (OS) of patients who underwent surgery first (SF) were compared to those who received NT prior to surgery.</p><p><strong>Results: </strong>Among 1191 patients with PASC who underwent curative intent resection, 208 (17.5%) received NT, whereas 983 (82.5%) underwent SF. Overall, NT was associated with improved OS compared with an SF approach (median 20.7 vs 15.9 months; p = 0.03). On multivariable Cox regression analysis, factors independently associated with improved OS included treatment at an academic/research facility, receipt of NT, and receipt of adjuvant therapy. Factors associated with decreased OS included Black race, positive surgical margins, worse comorbidity score, and higher cancer stage. There was no significant difference in OS between patients who received NT chemotherapy and radiation vs NT chemotherapy alone.</p><p><strong>Conclusion: </strong>Among patients with localized PASC, the receipt of NT prior to surgical resection was associated with improved OS outcomes. Future research is needed to clarify the optimal neoadjuvant treatment regimen, including the role of preoperative radiation, to enhance response to therapy and improve long-term outcomes.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"145"},"PeriodicalIF":1.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease.","authors":"Amir Mohammad Salehi, Shayan Bahadivand Chegini, Sara Danaei, Maryam Hasanzarrini, Fatemeh Shahbazi","doi":"10.1007/s12029-025-01266-0","DOIUrl":"10.1007/s12029-025-01266-0","url":null,"abstract":"<p><strong>Objective: </strong>This meta-analysis aims to systematically evaluate the relationship between inflammatory bowel disease (IBD) and the risk of developing pancreatic cancer (PC).</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Method: </strong>We searched PubMed (Medline), Web of Science, and Scopus up until September 8, 2024. To evaluate heterogeneity among the studies, we used the chi-square test and the I² statistic. An I² value exceeding 50% was considered indicative of substantial heterogeneity. We calculated estimates of odds ratios (OR), relative risks (RR), and hazard ratios (HR), along with their corresponding 95% confidence intervals (CI). The analysis was performed using a random-effects model. We established a significance level of less than 0.05 using Stata software, version 17.</p><p><strong>Results: </strong>We included a total of 17 studies in our analysis. Overall, patients with IBD showed a higher risk of developing PC, with an OR = 1.69 (95% CI: 1.48-1.93). Specifically, patients with Crohn's disease (CD) had an OR of 1.25 (95% CI: 1.10-1.41), while those with ulcerative colitis (UC) had an OR = 1.27 (95% CI: 1.10-1.45). Furthermore, patients with IBD accompanied by primary sclerosing cholangitis (PSC) displayed a significantly higher risk, with an OR = 3.12 (95% CI: 1.67-5.85). Additionally, there was no evidence of publication bias across all subgroups. Although there was no publication bias, we conducted a trim-and-fill analysis to investigate the small study effect. This analysis revealed that the results were influenced by omitted studies and that the pooled effects would be diluted if the omitted studies were included in the meta-analysis.</p><p><strong>Conclusion: </strong>CD and UC are associated with an increased risk of PC, with no significant difference in risk levels between the two conditions. However, having IIBD along with PSC increases the risk of PC threefold.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"147"},"PeriodicalIF":1.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy-A SEER-Based Study.","authors":"Shigang Xu, Liwei Duan, William C Cho, Shuai Jin, Linhao Ma","doi":"10.1007/s12029-025-01264-2","DOIUrl":"https://doi.org/10.1007/s12029-025-01264-2","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of neoadjuvant chemotherapy (NAC) for individuals with early-stage hepatocellular carcinoma (HCC) is still a subject of controversy and uncertainty. This study sought to create a risk categorization model using a nomogram to pinpoint patients with early-stage HCC that might derive benefits from NAC.</p><p><strong>Methods: </strong>This retrospective cohort study was based on data from the SEER Research Plus database (April 2021 release), covering the years 2006 to 2018. The definition of NAC was chemotherapy performed prior to surgery, while that of no NAC (No-NAC) was surgery without chemotherapy before the operation. We implemented stepwise Cox regression to discover prognostic factors and utilized these factors to develop a nomogram for forecasting the 3-, 5-, and 10-year cancer-specific survival (CSS) for patients with early-stage HCC. We utilized receiver operating characteristic curves, calibration curves, and decision curve analysis to evaluate the prognostic capacity of the nomogram. Finally, prognostic stratification was performed based on the optimal boundary value of the nomogram score, and we utilized the Kaplan-Meier method to analyze the survival rate.</p><p><strong>Results: </strong>A sum of 11,721 HCC patients was incorporated in the analysis. After adjustment through propensity score matching, the baseline characteristics of the NAC and No-NAC groups were not statistically different. A total of 4030 patients, with the clinical data of their marital status, tumor number, fibrosis, alpha fetoprotein, grade, age, T stage, tumor size, race, and surgical approach (i.e., 11 variables) were employed in the building of the nomogram. The constructed nomogram exhibited good discriminatory ability and accuracy in predicting CSS in patients with early-stage HCC. Based on the nomogram, individuals can be classified into three distinct risk categories. In the group identified as high-risk, the CSS of the patients was significantly enhanced by NAC.</p><p><strong>Conclusions: </strong>This study developed and validated a nomogram for predicting 3-, 5-, and 10-year CSS in early-stage HCC patients, incorporating demographic and clinical factors. Risk stratification identified high-risk patients who benefited significantly from NAC. These findings support personalized treatment decisions, though external validation is needed.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"144"},"PeriodicalIF":1.6,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}